UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 14, 2011
Brainstorm
Cell Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
333-61610
|
|
20-8133057
|
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File No.)
|
|
(IRS
Employer Identification No.)
|
|
110
East 59th
Street
|
|
|
New
York, New York
|
10022
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
(212)
557-9000
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01 Regulation FD
Disclosure
On
February 14, 2011, BrainStorm Cell Therapeutics, Inc. (“Company”) announced that
the U.S. Food and Drug Administration's Office of Orphan Products Development
has granted orphan drug designation for the Company’s NurOwn autologous adult
stem cell product candidate for the treatment of Amyotrophic Lateral Sclerosis
(ALS).
The
information contained in this Current Report on Form 8-K and the exhibits
attached hereto shall not be deemed to be “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall such information
or such exhibits be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. The information set
forth in this form 8-K and its exhibits shall not be deemed an admission as to
the materiality of any information within this report.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
February
15, 2011
|
Brainstorm
Cell Therapeutics Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Liat Sossover
|
|
|
|
|
Liat
Sossover
|
|
|
|
|
Chief
Financial Officer
|
|